-
Qian Wei, Chief Commercial Officer of Junshi Biotechnology, resigns
Time of Update: 2021-11-14
On November 3, Junshi Biotech formally announced to its employees that the chief commercial officer Qian Wei has recently resigned to the company due to personal development reasons.
-
The pharmaceutical industry accelerates innovation, and these companies have invested heavily in R&D in the first three quarters
Time of Update: 2021-11-14
. It is worth mentioning that since its listing in 2003, the operating income of the State Development Corporation has not improved, and the total net profit for the 18 years of listing has been about 480 million yuan .
-
Domestic pharmaceutical anti-monopoly efforts continue to increase, and another API company has been fined
Time of Update: 2021-11-14
In fact, in the pharmaceutical industry, there has always been a phenomenon in the field of APIs that related companies use market monopoly positions to manipulate prices for profiteering, or impose unreasonable trading conditions for unfair competition .
-
Announcement of the National Medical Products Administration on the addition of children's drug information to the instructions for haloperidol tablets and other varieties (No. 75 of 2021)
Time of Update: 2021-11-14
Recommendations for revisions to drug inserts of fluoxetine oral preparations National Food and Drug Administration May 28, 2021 Announcement No.
-
Overview of the application of prodrug technology in pulmonary inhalation preparations
Time of Update: 2021-11-14
By SharoCompared with systemic administration such as oral or injection, lung inhaled drugs directly enter the respiratory tract through a special drug delivery device to exert a therapeutic effect, and has shown obvious advantages in the treatment of asthma and chronic obstructive pulmonary disease .
-
How much cheaper has the common people's medication use for 3 years of national drug collection?
Time of Update: 2021-11-14
Has the cost of medicine for the common people dropped?Data map photo by Han Zhangyun Five batches of centralized procurement covers 218 drugs with an average price reduction of 54% In 2018, with the "4+7" kicking off, the improvement of drug quality and price reduction became the main theme .
-
The release of heavy documents, the Internet medical industry may welcome a major reshuffle
Time of Update: 2021-11-14
The proposal of the "Draft of Opinions" has just raised the barriers to entry for the industry, which will benefit the development of Internet diagnosis and treatment platforms that provide technical services, and will also bring more challenges to platforms that focus on medical e-commerce .
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Carbimazole Tablets (No. 80 of 2021)
Time of Update: 2021-11-14
5. The provincial drug supervision and administration department shall supervise and urge the drug marketing license holders of the above-mentioned drugs in the administrative area to do the corresponding manual revision and label and manual replacement work as required, and strictly investigate and deal with violations of laws and regulations in accordance with the law .
-
The first Sino-German Traditional Chinese Medicine Conference was held in Guangzhou to focus on the anti-epidemic effects of Chinese medicine
Time of Update: 2021-11-14
Photo by Chen Jimin China News Service, Guangzhou, November 4 (Cai Minjie, Cha Guanlin) The first Sino-German Traditional Chinese Medicine Conference was held in Guangzhou on the 4th.
-
Investment Collection: Core financial indicators reveal the development of online and offline retail pharmacies
Time of Update: 2021-11-14
Figure 1: Comparison of core data in the three quarterly reports of offline drugstoresData source: iFinD, Zhongkang Industrial Capital Research CenterOnline Internet pharmacies are represented by Alibaba Health, JD Health, Ping An Good Doctor, and Yiyao.
-
Approval of Sintilimab's new indication application for frustrated potential is still optimistic
Time of Update: 2021-11-14
However, due to unpredictable circumstances, Sintilimab received a drug notification for the first time in China, and the listing application for a single-drug second-line treatment of squamous non-small cell lung cancer was not approved .
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Propylthiouracil Preparations (No. 103 of 2021)
Time of Update: 2021-11-14
The marketing authorization holders of the above-mentioned drugs shall be in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, and in accordance with the requirements for the revision of the propylthiouracil preparation instructions (see attachment), before November 22, 2021 Report to the provincial drug supervision and administration department for the record .
-
Pharmaceutical companies showed strong willingness to invest in R&D, allowing R&D to be in the “C” position
Time of Update: 2021-11-14
Data shows that in the first three quarters of this year, some listed pharmaceutical companies invested more than 100 million yuan in research and development, and their share of revenue continued to increase .
In recent years, China's pharmaceutical companies have continuously increased their R&D investment.
-
Notice on the public solicitation of opinions on two standards including "Principles for Printing of Drug Traceability Codes (Draft for Solicitation of Comments)"
Time of Update: 2021-11-14
Please fill in the standard feedback form for soliciting opinions (see Annex 3), and feedback to the Information Center of the State Food and Drug Administration in the form of e-mail before July 20, 2021 .
-
10 pharmaceutical companies are favored by capital, accelerating the development of innovative drugs
Time of Update: 2021-11-14
On November 1st, Anjisheng Bio, which focuses on the research and development of innovative drugs for bone, joint and muscle diseases, announced the completion of the B round of US$70 million in financing .
-
Chinese pharmaceutical companies continue to make efforts in the field of anti-epileptic drugs
Time of Update: 2021-11-14
As recently, CSPC's anti-epileptic drug Enrivi (lacosamide tablets) was launched nationwide .
. In addition, in June, the State Food and Drug Administration issued a new drug approval document, and Renfu Pharmaceutical's carbamazepine tablets had been evaluated for consistency .
-
Traditional Chinese medicine is ushering in a broad space for development, and the status of decocting machine is becoming more and more prominent
Time of Update: 2021-11-14
Therefore, in terms of automation and information technology improvement of the decocting machine, the industry still needs to make continuous efforts to better contribute to the sustainable development of traditional Chinese medicine .
-
FDA approves multiple investigational new drug applications
Time of Update: 2021-11-14
” Theseus intends to initiate a phase I/II dose escalation and expansion clinical trial, which will include For patients with advanced GIST who have previously received treatment, the study is expected to start at the end of the fourth quarter of 2021 or the first quarter of 2022 .
-
WOO SWEE LIAN, Chairman of Wise Medicine, resigns and by-elections Fan Shixin as non-independent director
Time of Update: 2021-11-14
On November 2, Ruizhi Medicine issued an announcement stating that the company’s board of directors had recently received a written resignation report from the company’s chairman, Mr.
-
Announcement of the State Drug Administration on 16 batches of drugs that do not meet the requirements (No. 36 of 2021)
Time of Update: 2021-11-14
After inspection by 8 drug inspection institutions including Anhui Food and Drug Inspection and Research Institute, 16 batches of drugs including compound clotrimazole cream produced by 14 companies including Hebei Jiuzheng Pharmaceutical Co.
